This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EmblemHealth says Alexion monopolized US market for rare blood disease treatment

By Clayton Vickers ( April 16, 2025, 21:17 GMT | Insight) -- EmblemHealth has brought US antitrust claims against Alexion Pharmaceuticals, alleging the drug company and its wholly owned subsidiary AstraZeneca unlawfully delayed the introduction of biosimilar competition to its blockbuster drug Soliris through fraud.EmblemHealth brought US antitrust claims today against Alexion Pharmaceuticals, alleging the drug company and its wholly owned subsidiary AstraZeneca unlawfully delayed the introduction of biosimilar competition to its blockbuster drug Soliris through fraud....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections